Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
52 results about "ISOLATE COMPOUND" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Interleukin-1 receptor antagonists, compositions, and methods of treatment
ActiveUS20060094663A1Synthetic is simpleInhibition of activationNervous disorderPeptide/protein ingredientsArthritisDrug biological activity
Peptides that are designed to inhibit the biological activity of the IL-1R type 1 receptor and inhibit IL-1R / IL-1RacP related cell signaling and biological activity are disclosed. Compositions comprising IL-1R antagonists of the present invention are useful in the treatment of IL-1 related diseases or conditions such as arthritis, rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease as well as other chronic or acute inflammatory diseases. This invention also discloses an isolated compound having an IL-1R antagonist activity, said compound being selected from the group consisting of: a peptide comprising the amino acid sequence RYTPELX, wherein R, Y, T, P, E, L, refer to their corresponding amino acids, and X is selected from no amino acid and alanine (A); and a derivative of (a) wherein the derivative incorporates one, two or three amino acid modification selected from an amino acid addition, deletion or substitution in the RYTPEL portion of the peptide, and wherein said derivative maintains its antagonist IL-1R activity.
Owner:VALORISATION HSJ LLP
Methods for predicting the biological, chemical, and physical properties of molecules from their spectral properties
InactiveUS6898533B1Advantageously computer implementedParticle separator tubesColor/spectral properties measurementsNMR - Nuclear magnetic resonanceMass spectrometry
Methods are disclosed for establishing a quantitative relationship between spectral properties of molecules and a biological, chemical, or physical endpoint of the molecules. Spectral data including data from nuclear magnetic resonance, mass spectrometric, infrared, and ultraviolet-visible techniques are used along with endpoint data to train a pattern-recognition program. The training yields a spectral data-activity relationship that may be used to predict the endpoint value of a molecule from its spectral data alone. Methods for rapidly screening isolated compounds or mixtures of compounds based upon their spectral data are included.
Owner:UNITED STATES OF AMERICA
Probiotic compounds from Lactobacillus GG and uses therefor
InactiveUS20070123460A1Bolster a cell's defenses against inflammationModulate signal transduction pathwaysPeptide/protein ingredientsAntipyreticBacteroidesLactobacillus GG
The invention provides methods and compositions for the treatment of inflammatory disorders, such as inflammatory bowel diseases (IBDs). The use of bacteria-free, probiotic-derived compounds instead of live bacteria provides a safety advantage over the use of live bacteria. In addition, the administration of isolated compounds will provide more reliable dosing, greater simplicity, and improved consistency than is found in administering probiotics, which is dependent on both establishing and maintaining bacterial colonization.
Owner:UNIVERSITY OF CHICAGO
Androgen Receptor Modulators
Treatment of Diseases caused by Disturbances of the Activity of the Androgen Receptor uses of compounds of Formula (I): (as defined herein), for the treatment of diseases caused by disturbances of the activity of androgen receptor are provided: Formula (I). Isolated compounds of Formula (I) are also provided.
Owner:KARO BIO AB
Process for the preparation of oxcarbazepine and related intermediates
InactiveUS20050282797A1High yieldSimple methodBiocideOrganic chemistryOrganic solventChlorosulfonyl isocyanate
A process for preparing Oxcarbazepine III comprising: a) reacting oximinostilbene IV with chlorosulfonyl isocyanate in an inert organic solvent and isolating compound V b) hydrolyzing compound V to form crude Oxcarbazepine III c) purifying oxcarbazepine.
Owner:APOTEX PHARMACHEN INC
Irradiated crosslinking low-smoke halogen-free flame-retardant isolating compound and sheathing compound for solar cables
InactiveCN101608033AImprove cladding integrityImprove hydrophobicityPlastic/resin/waxes insulatorsInsulated cablesMethacrylateProcedure Agents
The invention relates to an irradiated crosslinking low-smoke halogen-free flame-retardant insulating compound and a sheathing compound for solar cables, which are characterized by taking ethylene-methyl acrylate copolymer (EMA) or ethylene-butyl acrylate copolymer objects (EBA) as basal resin, taking functionalized polyolefin resin as compatilizer, taking magnesium oxide and silicon resin as fire retardant, and then mixing antioxidant, UV absorbent, anti-copper agent, crosslinking sensitizer and processing agent together. The irradiated crosslinking low-smoke halogen-free flame-retardant isolating compound and the sheathing compound for solar cables have the advantages of higher temperature resistant class, longer service life, excellent squeezing performance and good electrical insulation performance. Cables squeezed from the irradiated crosslinking low-smoke halogen-free flame-retardant insulating compound and the sheathing compound can pass the flood and pressure test.
Owner:SHANGHAI KAIBO SPECIAL CABLE FACTORY
Damping vibration-isolating compound track bed for metro and construction method thereof
The invention relates to a damping vibration-isolating compound track bed for a metro and a construction method thereof. The track bed comprises concrete layers and EPS (Expanded Poly Styrol) layers which are arranged at intervals, wherein the quantity of the concrete layers is three or four; the quantity of the EPS layers is two or three; the top layer and the bottom layer are both concrete layers; the EPS layers and the poured concrete layers are fixed by small steel chisels; the concrete layers meet the C35 standard; a demand on the density of the EPS layers is 12-15kg / m<3>; and a grain size of EPS grains is 1-2mm. The damping vibration-isolating compound track bed meets the demands on strength and long-term stability, has certain elasticity, has an obvious damping vibration-isolating function and has the energy attenuation above 50-60dB.
Owner:SOUTHEAST UNIV
Method for screening anti-adherent compounds on polymers for preventing biofilm formation
The instant invention provides a live labeling microorganism assay for screening a one-bead one-compound library to identify synthetic anti-adherent compounds for blocking biofilm formation. The compounds of libraries may be peptides, small molecules, nucleic acids, other types of molecules or a combination of the foregoing. The live labeling microorganisms are incubated with a one-bead one-compound library for a long period with fresh-labeled bacteria and nutrition replacement in regular intervals. Those beads without bacterial adhesion are transferred into nutritional agar for the culture. The true anti-adherent beads are isolated and the sequences of each isolated compound-bead are determined with sequencer. The anti-adherent compounds identified in this invention are proved to possess long-term effect of blocking bacterial adhesion and biofilm formation. Thus the instant invention provides a unique and powerful method to identify anti-adherent compounds from library more quickly and reliably than current state-of-the-art technology allows.
Owner:BIOPATH LAB DELAWARE
Natural sweetener compositions
InactiveUS20180132514A1Low calorie contentSugar food ingredientsAcidic food ingredientsSweetnessSweet taste
Owner:SENSORYGEN INC
Application of caffeoylquinic acid and its derivatives in the preparation of anti-complement drugs
InactiveCN102266318ASignificant anticomplement activityLow effective concentrationOrganic active ingredientsImmunological disordersDiseaseCaffeoylquinic acid
The invention provides the application of caffeoylquinic acid and its derivatives in the preparation of anti-complement drugs. The present invention extracts and separates the caffeoylquinic acid compounds obtained from Shamrock, through in vitro experiments, it is confirmed that the cell hemolysis caused by the activation of the classic pathway of the complement system is inhibited, indicating that there is an anti-complement effect. The activity is stronger than that of the total extract of S. sageris, and it is a kind of good complement inhibitor, which can be used to prepare new anti-complement drugs and treat various diseases caused by abnormal activation of complement, and has low effective concentration and low toxicity. The drug is safe, the source of raw materials is abundant, and it has great clinical application value. Caffeoylquinic acid and its derivatives are shown in the following structural formula I: Formula I wherein R1, R2, R3, or R4 can be the same or different, and they are H or caffeoyl respectively, provided that they cannot be H at the same time; R5 is H , CH3, CH2CH3 or CH2CH2CH2CH3.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Methods for isolating compounds
ActiveUS20190274332A1Avoid costly and mechanically complicated stepMembranesUltrafiltrationCompound (substance)Turbidity
The present invention in its broadest aspect relates to a method for reducing glycoalkaloid content and turbidity of an aqueous phase comprising compounds selected from two or more of PA, PI, PPO, LipO, pectin, lipid, glycoalkaloid and phenolic compounds of which at least one compound is selected from PA, PI, LipO and PPO; a) providing an aqueous phase comprising compounds selected from two or more of PA, PI, PPO, LipO, pectin, lipid, glycoalkaloid and phenolic compounds of which at least one compound is selected from PA, PI, LipO and PPO; and b) performing one or more steps to reduce the concentration of solanine in the dry matter of the aqueous phase with at least 15 percent, such as at least 20% such as at least 25% and to achieve an optical density at 620 nm of the remaining aqueous phase of less than 0.7; such as less than 0.5; such as less than 0.3; such as less than 0.2 such as less than 0.1 and thereby obtaining an aqueous phase having reduced glycoalkaloid content and turbidity compared to an untreated aqueous phase.
Owner:DUYNIE HLDG
Ethyl acetate extract from guignardia used to treat an individual infected by fungi or bacteria
The present invention refers to extracts from the fungus Guignardia sp., and also a new isolate compound from the aforementioned extract, both having antimicrobial activities, particularly antibacterial and antifungal activities, and their use in pharmaceutical compositions. The new compound, isolated from the extract of the fungus Guignardia sp., presents a dioxolanone ring, having the following formula: ##STR1##
Owner:FUNDACAO OSWALDO CRUZ FIOCRUZ
Methods and compositions for the treatment of cancer
InactiveUS20100069481A1Improves clinical characteristicReduce volumeBiocideAnimal repellantsCancer cellApoptosis
Isolated compounds and combinations of isolated compounds isolated from Scutellaria barbata D. Don are effective in the generation of reactive oxygen species, induction of DNA damage and induction of apoptosis in cancer cells. The compounds and combinations may be prepared as pharmaceutical compositions for administration to mammals, such as humans, for the treatment of solid cancers, such as epithelial cancers. Such epithelial cancers include breast cancer and ovarian cancers.
Owner:BIONOVO
Antitumour Compounds
The invention relates to novel antitumor compounds of general formulaas well as their corresponding pharmaceutically acceptable salts, derivatives, prodrugs and stereoisomers. These compounds can be obtained by isolating a sponge from family Theonellidae, genus Theonella and species swinhoei, and forming derivatives from the isolated compounds. These compounds have cytotoxic activity and can be used for the treatment of the cancer.
Owner:PHARMA MAR U
Process for the preparation of efavirenz
InactiveUS20110077397A1Simple and efficient and cost-effective processShorten the timeOrganic chemistryOrganic solventPhotochemistry
A simple, cost-effective process for preparation of efavirenz of formula (I) comprising reacting a solution of 5-chloro-α-(cyclopropylethynyl)-2-amino-α-trifluoromethyl) benzene methanol of formula (II) in an organic solvent with triphosgene in the presence of an inorganic base at a temperature range −5° C. to 25° C., adding water and isolating compound of formula (I).
Owner:EMCURE PHARAMACEUTICALS LTD
Interleukin-1 receptor antagonists, compositions, and methods of treatment
InactiveUS20100041609A1Synthetic is simpleInhibition of activationPeptide/protein ingredientsAntipyreticArthritisDrug biological activity
Peptides that are designed to inhibit the biological activity of the IL-1R type 1 receptor and inhibit IL-1R / IL-1RacP related cell signaling and biological activity are disclosed. Compositions comprising IL-1R antagonists of the present invention are useful in the treatment of IL-1 related diseases or conditions such as arthritis, rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease as well as other chronic or acute inflammatory diseases. This invention also discloses an isolated compound having an IL-1R antagonist activity, said compound being selected from the group consisting of: a peptide comprising the amino acid sequence RYTPELX, wherein R, Y, T, P, E, L, refer to their corresponding amino acids, and X is selected from no amino acid and alanine (A); and a derivative of (a) wherein the derivative incorporates one, two or three amino acid modification selected from an amino acid addition, deletion or substitution in the RYTPEL portion of the peptide, and wherein said derivative maintains its antagonist IL-1R activity.
Owner:VALORISATION RECH SOC & COMMANDITE
Salts and hydrates of antipsychotics
The present invention relates to a novel salt of (3aR,4S,7R,7aS)-2-[((1R,2R)-2-{[4-(1,2-benzisothiazol-3-yl)-piperazin-1-yl]methyl}cyclohexyl)methyl]hexahydro-1H-4,7-methanisoindol-1,3-dione and hydrates thereof, to methods for preparing the novel salt and its hydrates. In one aspect, the present invention provides a compound which is lurasidone dihydrochloride. In another aspect, the present invention provides a process for preparation of lurasidone dihydrochloride comprising: (i) mixing lurasidone free base in an organic solvent system; (ii) subjecting step (i) mixture to acid proton source; and (iii) isolating compound of lurasidone dihydrochloride.
Owner:SHASUN CHEM & DRUGS LTD
Apparatus and method for vibrational isolation of compounds
The present invention is directed to a method and device to isolate compounds from plant material using vibrational pulsing, vibrational decanting, vibrational sieving and vibrational rinsing. A susceptible liquid is generated by vibrational agitation, decanted when in a vibrating container and then collected by passing over a series of vibrating screens and then rinsed with water while collected on the vibrating screens and the residue collected. The isolated compound can either be collected in the decant or retained on the screens. In an embodiment of the invention, the vibrational rinsing step reduces unwanted impurities isolated.
Owner:JP LOVE
Process for the preparation of oxcarbazepine and related intermediates
InactiveUS7125987B2High yieldSimple methodBiocideOrganic chemistryOrganic solventChlorosulfonyl isocyanate
A process for preparing Oxcarbazepine IIIcomprising:a) reacting oximinostilbene IV with chlorosulfonyl isocyanate in an inert organic solvent and isolating compound Vb) hydrolyzing compound V to form crude Oxcarbazepine IIIc) purifying oxcarbazepine.
Owner:APOTEX PHARMACHEN INC
Estrogenic compounds and their methods of use
Isolated compounds and combinations of isolated compounds isolated from Epimedium grandiflorum Morr. are estrogenic, and can be used to treat one or more symptoms of menopause and / or ER-positive cancer. The compounds and combinations may be prepared as pharmaceutical compositions for administration to mammals, such as humans, for the treatment of solid cancers, such as epithelial cancers. Such epithelial cancers include breast cancer, uterine cancer, cervical cancer, ovarian cancer, vulvar cancer, endometrial cancer.
Owner:BIONOVO
Antipsychotic agents and standardized antipsychotic fractions from Rauwolfia tetraphylla and process of their isolation
Owner:COUNCIL OF SCI & IND RES
Process for Preparing Atazanavir Sulphate
The present invention relates to a process for the preparation of Compound (A):wherein the process comprises contacting atazanavir base (Compound (II))with sulphuric acid in a combination of two or more solvents and isolating compound (A). The present invention also relates to substantially pure Compound (A), and to Compound (A) devoid of mesityl oxide impurity. Mesityl oxide has the following formula:
Owner:CIPLA LTD
Method for isolating compound metal grid from back electrode during large-area preparation of dye sensitized solar cell (DSSC)
InactiveCN102324328AHigh light transmittanceFully absorbedLight-sensitive devicesSolid-state devicesSolar cellSizing
The invention provides a method for isolating a compound metal grid from a back electrode during large-area preparation of a dye sensitized solar cell (DSSC). The method comprises the following steps of: (1) sputtering a compound metal grid of Ti and Al on transparent conducting glass; (2) preparing a TiO2 nanoparticle film on a transparent conducting substrate by using a TiO2 sizing agent with ascreen printing method; and (3) heating the substrate on which the TiO2 sizing agent is printed to fully vaporize or oxidize organic matters in the TiO2 sizing agent, wherein an oxide of a Ti metal on an upper layer of the compound metal grid is taken as an isolated layer. Due to the adoption of the method provided by the invention, the isolation between an Al metal grid and an electrolyte duringthe encapsulation of the dye-sensitized solar cell is realized effectively, and the problem of internal short circuit of the DSSC is solved; and low-cost metals, i.e., Al and Ti are adopted instead of precious metals, i.e., Pt, Au and the like in the conventional process, so that a firm foundation is laid for the industrial mass production of DSSCs.
Owner:PEKING UNIV
Isolated hydroxy and N-oxide metabolites and derivatives of O-desmethylvenlafaxine and methods of treatment
The present invention provides novel isolated compounds characterized as metabolites or derivatives of desmethylvenlafaxine including hydroxy-DV metabolites, hydroxy-DV-glucuronide metabolites, N-oxide-DV metabolites, and benzyl-hydroxy-DV metabolites. The invention includes pharmaceutical compositions comprising any of the metabolites or derivatives of the invention in combination with a pharmaceutically acceptable carrier or excipient. The invention also includes a method of treating at least one central nervous system disorder in a mammal comprising providing to a mammal in need thereof an effective amount of the compounds of the invention.
Owner:WYETH LLC
Rhodiola rosea extracts and isolated compounds and uses thereof for treating neurodegenerative diseases
ActiveCN103857400AOrganic active ingredientsNervous disorderDementia with Lewy bodiesSynucleinopathies
This invention relates to extract, fractions and isolated compound of Rhodiola rosea, and uses thereof for treating neuropathological and neurodegenerative diseases. The extracts and compounds of the present invention inhibit the aggregation of alpha-synuclein. In one embodiment, Rhodiola rosea extracts and compounds of the present invention can be used to treat synucleinopathies including PD, dementia with Lewy bodies, pure autonomic failure, multiple system atrophy, and Alzheimer's disease.
Owner:THE HONG KONG UNIV OF SCI & TECH
Isolated hydroxy and n-oxide metabolites and derivatives of O-desmethylvenlafaxine and methods of treatment
The present invention provides novel isolated compounds characterized as metabolites or derivatives of desmethylvenlafaxine including hydroxy-DV metabolites, hydroxy-DV-glucuronide metabolites, N-oxide-DV metabolites, and benzyl-hydroxy-DV metabolites. The invention includes pharmaceutical compositions comprising any of the metabolites or derivatives of the invention in combination with a pharmaceutically acceptable carrier or excipient. The invention also includes a method of treating at least one central nervous system disorder in a mammal comprising providing to a mammal in need thereof an effective amount of the compounds of the invention.
Owner:WYETH LLC
Extract of fraxinus excelsior seeds and therapeutic applications therefor
ActiveUS20120058210A1Increase the number ofIncrease in sizeBiocideOrganic active ingredientsTherapeutic treatmentAdemetionine
A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior seed extract includes, inter alia, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl)methyl ester, commonly called excelside A, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl) 2-(4-hydroxyphenyl)ethyl ester, commonly called excelside B, and the compounds GI5, GI3, nuzhenide, and oleoside dimethyl ester.
Owner:NATUREX SA
Application of gentiopicrin in preparing medication for restraining hepatitis B virus
InactiveCN1259054CEnhanced inhibitory effectOrganic active ingredientsDigestive systemHepatitis B virusBULK ACTIVE INGREDIENT
The application of the active ingredient gentiopicroside in the preparation of drugs for inhibiting hepatitis B virus. The active ingredient gentiopicroside is a compound extracted and separated from the commonly used traditional Chinese medicine Gentiana quinquefolium in my country. The active ingredient gentiopicroside is mixed with pharmaceutically acceptable carriers in preparations such as those suitable for enteral and parenteral administration. Organic or inorganic solid or liquid excipients are mixed, and the pharmaceutical preparation can be in solid form such as tablet, capsule, powder, pill, granule, or in liquid form such as injection, emulsion, etc. Gentiopicroside was prepared into injections, and the drug efficacy test showed that ducks infected with duck hepatitis B virus were treated with intramuscular injection of gentiopicroside on the 7th day after infection. The inhibitory effect of duck serum DHBV-DNA level is remarkable, and the statistical processing results have very significant and significant differences, inhibitory effect (P<0.01-0.05), and the inhibitory effect of three batches of experiments can be repeated.
Owner:HARBIN GLORIA PHARMA CO LTD
Extract Of Fraxinus Excelsior Seeds And Therapeutic Applications Therefor
ActiveUS20090117214A1Increase the number ofIncrease in sizeBiocideSugar derivativesBlood plasmaAdemetionine
A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior seed extract includes, inter alia, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-β-D-glucopyranosyl-β-D-glucopyranosyl) oxy]-3,4-dihydro-5-(methoxycarbonyl)methyl ester, commonly called excelside A, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl) 2-(4-hydroxyphenyl)ethyl ester, commonly called excelside B, and the compounds G15, G13, nuzhenide, and oleoside dimethyl ester.
Owner:NATUREX INC
Novel compounds from antrodia camphorata
Disclosed herein are isolated compounds or pharmaceutically acceptable salts thereof, which exhibit immunostimulatory or anti-inflammatory effects. The compounds are isolated from the fruiting body of A. camphorata in a solid culture. Also disclosed are methods of stimulating immune responses and / or treating an inflammatory disorder with these compounds and pharmaceutical compositions including the compounds or pharmaceutically acceptable salts thereof.
Owner:WELL SHINE BIOTECH DEV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com